Business Wire

SentryOne Introduces Database Monitoring Edition Targeted to Smaller Environments

Share

SentryOne launched SQL Sentry Essentials, a new edition of the company’s top-rated SQL Sentry database monitoring product that provides core monitoring capabilities for up to five database targets at $995 per targeted SQL Server instance.

SQL Sentry Essentials includes the most frequently used features for monitoring, diagnosing, and optimizing SQL Server performance. This new edition is ideal for small and medium companies as well as larger organizations that need to monitor specific data systems within their environment.

“SQL Sentry Essentials is a perfect choice when you need to deploy SQL Server performance management at a small scale, or if you need enterprise capabilities but aren’t ready to build the case for an investment in a larger database performance management solution,” said Jason Hall, SentryOne VP of Product Management. “This new edition gives you the crucial information you need to get to the root of your SQL Server performance problems.”

SentryOne introduced SQL Sentry Essentials to meet the industry need for a monitoring solution that provides powerful core monitoring capabilities but excludes advanced features valued by larger enterprises.

“Everyone needs to monitor their databases, but not everyone needs all the advanced features of our flagship product, SQL Sentry,” said Andy Mallon, SentryOne Product Manager. “We’ve distilled the feature list down to the most essential monitoring capabilities, now available as SQL Sentry Essentials. This new edition is a powerful, capable solution for companies who need to monitor up to five instances, all at a very attractive price.”

SQL Sentry Essentials includes five of the most frequently used SQL Sentry features, helping data pros view essential real-time performance metrics, identify high-impact queries that are slowing performance, use proactive notifications to prevent problems, analyze SQL Server blocking and deadlocks, and view Windows resource metrics.

SentryOne customer David Klee, Heraflux Technologies Founder and Chief Architect, said that one of the features included in SQL Sentry Essentials, the Performance Analysis Dashboard, gives actionable information that helps data pros quickly identify and address problems.

“Lots of other utilities provide 'pretty' dashboards that do not provide much meaning,” Klee said. “SentryOne gives you a dashboard that presents vital performance statistics. Anything unusual jumps out at you and helps you refine how you approach that server.”

SQL Sentry Essentials is priced at US$995 per license, which can be applied to one targeted SQL Server instance, plus US$199 for annual maintenance (first year required). Subscription pricing is available at US$50 monthly (annual commitment required).

For more information, visit sentryone.com/sqlsentry-essentials.

About SentryOne
SentryOne empowers Microsoft data professionals to build, test, document, and monitor SQL Server, Azure SQL Database, and the Microsoft Data Platform. We help companies accelerate performance across the data lifecycle with unmatched scalability, best-in-industry customer support, and the most powerful data performance management capabilities available. Our team includes a core group of Microsoft MVPs and staff located in Charlotte, NC, Jacksonville, FL, Salem, NH, and Dublin, Ireland. Learn more at SentryOne.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Megan Keller
Communications Manager
media@sentryone.com

Erik Arvidson
Matter for SentryOne
978-518-4542
sentryone@matternow.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye